Scarica l'app Stockscreener
5.01
2.04%
0.10
Precedente Chiudi:
$4.91
Aprire:
$4.96
Volume 24 ore:
936.66K
Relative Volume:
0.75
Capitalizzazione di mercato:
$325.95M
Reddito:
$297.18M
Utile/perdita netta:
$-51.64M
Rapporto P/E:
-6.2368
EPS:
-0.8033
Flusso di cassa netto:
$-50.72M
1 W Prestazione:
-9.40%
1M Prestazione:
+16.51%
6M Prestazione:
-30.32%
1 anno Prestazione:
-61.34%
Intervallo 1D:
$4.83
$5.03
Intervallo di 1 settimana:
$4.83
$5.67
Portata 52W:
$4.0913
$13.66
Evolus Inc Stock (EOLS) Company Profile
Nome
Evolus Inc
Settore
Telefono
(949) 284-4555
Indirizzo
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
5.01 | 325.95M | 297.18M | -51.64M | -50.72M | -0.8033 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.77 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.62 | 48.81B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.03 | 44.67B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.57 | 33.27B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
536.12 | 23.50B | 3.18B | 1.33B | 1.04B | 27.90 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Downgrade | Needham | Buy → Hold |
| 2025-04-17 | Iniziato | BTIG Research | Buy |
| 2024-01-29 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-06-23 | Iniziato | Needham | Buy |
| 2022-05-12 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-01-20 | Aggiornamento | Truist | Hold → Buy |
| 2021-05-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-04-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-24 | Downgrade | Truist | Buy → Hold |
| 2020-07-07 | Downgrade | Mizuho | Buy → Neutral |
| 2020-02-06 | Ripresa | Mizuho | Buy |
| 2019-11-26 | Iniziato | SVB Leerink | Outperform |
| 2019-09-05 | Ripresa | Mizuho | Buy |
| 2019-06-28 | Iniziato | Wells Fargo | Market Perform |
| 2019-06-11 | Iniziato | Barclays | Underweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-02-14 | Iniziato | H.C. Wainwright | Buy |
| 2019-01-29 | Iniziato | Stifel | Buy |
Mostra tutto
Evolus Inc Borsa (EOLS) Ultime notizie
Evolus, Inc. Files Form 8-K Announcing Executive Changes and Company Information (March 13, 2026) - Minichart
Evolus reclassifies Vikram Malik to Class II director to balance board - Investing.com
Vikram Malik reclassified to Class II director at Evolus - TradingView
How The Narrative On Evolus (EOLS) Is Resetting After Cautious 2025 And 2026 Guidance - Yahoo Finance
Evolus at Leerink Global Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
New Highs: What is the earnings history of Evolus IncMarket Growth Review & High Win Rate Trade Tips - baoquankhu1.vn
Evolus Earnings Call Signals Growth Amid Headwinds - The Globe and Mail
Evolus, Inc. (NASDAQ:EOLS) Q4 2025 earnings call transcript - MSN
Market Outlook: What analysts say about Evolus Inc stockTrade Ideas & Short-Term High Return Strategies - baoquankhu1.vn
Bank Watch: Can Evolus Inc navigate macro headwindsPortfolio Growth Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
(EOLS) Risk Channels and Responsive Allocation - Stock Traders Daily
Can Evolus Inc. stock maintain growth trajectoryChart Signals & Community Consensus Trade Alerts - Naître et grandir
Evolus (NASDAQ:EOLS) Rating Increased to Buy at Wall Street Zen - MarketBeat
Why Evolus Stock Soared Today - AOL.com
Evolus, Inc. (EOLS) matches Q4 earnings estimates - MSN
Evolus, Inc. (NASDAQ:EOLS) Q4 2025 Earnings Call Transcript - Insider Monkey
Data Privacy Compliance Risks Threaten Evolus’s Operations and Financial Health - TipRanks
BTIG Reiterates Buy Rating for Evolus (EOLS) with $13 Target | E - GuruFocus
Evolus (EOLS) Nears Breakeven In Q4 EPS Challenging Prolonged Loss Narratives - simplywall.st
Evolus Q4 2025 slides: revenue growth continues despite forecast miss By Investing.com - Investing.com Australia
EOLS SEC FilingsEvolus 10-K, 10-Q, 8-K Forms - Stock Titan
Evolus posts record rally after Q4 beat (EOLS:NASDAQ) - Seeking Alpha
Midday Stock Roundup: Evolus, Xponential up - Orange County Business Journal
Evolus Q4 2025 slides: revenue growth continues despite forecast miss - Investing.com Nigeria
Evolus Up Over 26%, on Pace for Largest Percent Increase Since January 2025 -- Data Talk - 富途牛牛
Evolus (NASDAQ:EOLS) Issues Quarterly Earnings Results - MarketBeat
Evolus' (EOLS) Buy Rating Reaffirmed at BTIG Research - MarketBeat
Evolus, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
US Stock Movement | Evolus rises over 16% pre-market as Q4 revenue growth achieves breakeven, positive guidance for this quarter - Bitget
Evolus (EOLS) Projects Growth with Strategic Initiatives and New Product Launches - GuruFocus
Evolus earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Evolus Inc (EOLS) Q4 2025 Earnings Call Highlights: Strong Reven - GuruFocus
Evolus Q4 2025 Earnings Call Transcript - MarketBeat
Aug Sectors: What analysts say about Evolus Inc stockTrade Risk Assessment & AI Enhanced Trading Alerts - baoquankhu1.vn
Earnings call transcript: Evolus misses Q4 2025 revenue forecast, stock dips - Investing.com South Africa
Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates - Bitget
Evolus Q4 Earnings Call Highlights - MarketBeat
Evolus Shares Up 17% on Q4, Full Year Earnings - Orange County Business Journal
Evolus, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:EOLS) 2026-03-03 - Seeking Alpha
Evolus (EOLS) Q4 2025 Earnings Call Transcript - AOL.com
Evolus (NASDAQ: EOLS) outlines 2025 losses, Jeuveau and Evolysse growth plans - Stock Titan
EOLS Projects Strong Financial Growth Through 2028 - GuruFocus
Evolus : Investor Presentation - marketscreener.com
Evolus Incenters loan and security agreement with Eclipse Business Capital on March 3, 2026SEC filing - marketscreener.com
EOLS Reports Strong Q4 Revenue Surpassing Expectations - GuruFocus
Evolus Posts Q4 Breakeven Results, Revenue Rises; Shares Gain After Hours - marketscreener.com
Evolus 2025 10-K: $297.2M Revenue, $(0.80) EPS - TradingView
Evolus Secures New Credit Facility and Reports Profitability - TipRanks
Evolus Q4 Earnings Summary & Key Takeaways - Benzinga
Evolus Inc. (EOLS) Stock Rises on Q4 2025 Earnings - Quiver Quantitative
Evolus (NASDAQ: EOLS) wins $30M credit line and 12% 2025 sales rise - Stock Titan
Evolus Inc Azioni (EOLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.15%
3.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):